4 min. Read

The case against Proteus-Otsuka’s digital med. AliveCor’s 6th CEO

Issue 012.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a doubly lucky 77 percent open rate. Here's what's happening this week:

  • Your editor has been waxing nostalgic on Twitter about digital health semantics (pre-2008 to present) with appearances from Golden Oldies like uHealth, wireless health and more.
  • Livongo went public this morning at $28 a share, higher than its already upgraded share price range. Health Catalyst also IPO'd today.
  • The American Telemedicine Association announced Partners HealthCare's Dr. Joseph Kvedar is its new president-elect.
  • FiercePharma pointed out that Pear Therapeutics' insomnia and depression DTx, Somryst, appears to be its first effort to go to market without its pharma partner Novartis. Will Pear go solo with that one?
  • Finally, STAT resurfaced the important issue of wearable device

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Better Therapeutics shuts down. Mahana-Cara Care
5 min. Read
HCPCS and CPT decisions. Akili results. Click trials
7 min. Read
De Novo: Samsung Galaxy Watch gets OTC sleep apnea detection
7 min. Read
Facebook’s RCT for AI bot Zenny. More trials
7 min. Read
FDA de novo for Google smartphone thermometer.
6 min. Read
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
5 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last